PHASE I-II STUDY OF IRINOTECAN (CPT-11) AND GEFITINIB IN PATIENTS (PTS) WITH GEFITINIB FAILURE FOR NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Horiike, A. [1 ]
Ohyanagi, F. [1 ]
Kudo, K. [1 ]
Miyauchi, E. [1 ]
Kasahara, K. [2 ]
Horai, T. [1 ]
Nishio, M. [1 ]
机构：
[1] Canc Inst Hosp, Thorac Oncol Ctr, Tokyo, Japan
[2] Kanazawa Univ Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：108 / 108
页数：1
相关论文
共 50 条
  • [1] Phase I-II study of irinotecan (CPT-11) and gefitinib in patients (pts) with gefitinib failure for non-small cell lung cancer (NSCLC)
    Horiike, A.
    Ohyanagi, F.
    Okano, Y.
    Kudo, K.
    Miyauchi, E.
    Kasahara, K.
    Horai, T.
    Nishio, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
    Horiike, A.
    Kudo, K.
    Miyauchi, E.
    Ohyanagi, F.
    Kasahara, K.
    Horai, T.
    Nishio, M.
    BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1131 - 1136
  • [3] Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
    A Horiike
    K Kudo
    E Miyauchi
    F Ohyanagi
    K Kasahara
    T Horai
    M Nishio
    British Journal of Cancer, 2011, 105 : 1131 - 1136
  • [4] Phase I and pharmacokinetic (FK) study of irinotecan (CPT-11) and amrubicin (AMR) in non-small cell Lung Cancer (NSCLC).
    Masuda, N
    Yanaihara, T
    Onoda, S
    Yamamoto, M
    Ryuge, S
    Hagiri, S
    Wada, M
    Kato, E
    Mitsufuji, H
    Yanase, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 152S - 152S
  • [5] Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC)
    Kakolyris, S
    Kouroussis, C
    Souglakos, J
    Androulakis, N
    Mavroudis, D
    Kalbakis, K
    Kotsakis, A
    Sara, E
    Agelaki, S
    Samonis, G
    Georgoulias, V
    ANNALS OF ONCOLOGY, 1998, 9 : 96 - 96
  • [6] A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer
    Hotta, K
    Ueoka, H
    Kiura, K
    Tabata, M
    Kuyama, S
    Satoh, K
    Kozuki, T
    Hisamoto, A
    Hosokawa, S
    Fujiwara, K
    Tanimoto, M
    LUNG CANCER, 2004, 45 (01) : 77 - 84
  • [7] Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Milton, DT
    Kris, MG
    Azzoli, CG
    Gomez, JE
    Heelan, R
    Krug, LM
    Pao, W
    Pizzo, B
    Rizvi, NA
    Miller, VA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 646S - 646S
  • [8] A phase II trial of weekly paclitaxel (P) and gefitinib (G) in patients (pts) with gefitinib-refractory or -resistant non-small cell lung cancer (NSCLC).
    Kasahara, K
    Sone, T
    Kimura, H
    Yoshimoto, A
    Araya, T
    Iwasa, KI
    Shirasaki, H
    Shintani, H
    Fujimura, M
    Nakao, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 639S - 639S
  • [9] Phase I/II trial of paclitaxel (P), carboplatin (C), and irinotecan (CPT-11) in advanced, metastatic non-small cell lung cancer (NSCLC)
    Socinski, MA
    Miller, LL
    Sandler, AB
    Israel, VK
    Hanover, CK
    Locker, PL
    Elfring, GL
    Natale, RB
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 23 - 23
  • [10] Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer
    Fumihiro Oshita
    Kouzo Yamada
    Haruhiro Saito
    Kazumasa Noda
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 465 - 470
12345